在初治2型糖尿病患者中起始使用甘精胰岛素300 U/mL后治疗满意度的临床意义改善：真实世界ATOS研究的事后分析 - Suppr

Clinically meaningful improvements in treatment satisfaction in insulin-naïve people with type 2 diabetes post initiation of insulin glargine 300 U/mL: A post hoc analysis of real-world ATOS study.

作者信息

Snoek Frank, Galstyan Gagik, Khan Niaz, Tirosh Amir, Kesavadev Jothydev, Vargas-Uricoechea Hernando, Baghous Houssem, Mabunay Maria Aileen, Grulovic Natasa, Corp Dit Genti Valerie, Msihid Jerome, Harris Stewart

机构信息

Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.

Endocrinology Research Centre of Health Care Ministry of Russian Federation, Moscow, Russian Federation.

出版信息

Diabetes Obes Metab. 2025 Jul;27(7):4011-4016. doi: 10.1111/dom.16415. Epub 2025 Apr 28.

DOI:10.1111/dom.16415

PMID:40292754

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12146449/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7aa8/12146449/96ceb0d8fabc/DOM-27-4011-g001.jpg

相似文献

Clinically meaningful improvements in treatment satisfaction in insulin-naïve people with type 2 diabetes post initiation of insulin glargine 300 U/mL: A post hoc analysis of real-world ATOS study.

Diabetes Obes Metab. 2025 Jul;27(7):4011-4016. doi: 10.1111/dom.16415. Epub 2025 Apr 28.

Real-world effectiveness and safety of insulin glargine 300 U/ml in insulin-naïve people with type 2 diabetes in the Latin America region: A subgroup analysis of the ATOS.

Diabetes Obes Metab. 2023 Jan;25(1):238-247. doi: 10.1111/dom.14868. Epub 2022 Oct 9.

Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naïve People with Type 2 Diabetes: the ATOS Study.

Diabetes Ther. 2022 Jun;13(6):1187-1202. doi: 10.1007/s13300-022-01266-4. Epub 2022 May 9.

Real-World Health Outcomes of Insulin Glargine 300 U/mL vs Insulin Glargine 100 U/mL in Adults With Type 1 and Type 2 Diabetes in the Canadian LMC Diabetes Patient Registry: The REALITY Study.

Can J Diabetes. 2019 Oct;43(7):504-509.e1. doi: 10.1016/j.jcjd.2019.04.012. Epub 2019 May 8.

Real-World Outcomes of Individualized Targeted Therapy with Insulin Glargine 300 Units/mL in Insulin-Naïve Korean People with Type 2 Diabetes: TOBE Study.

Adv Ther. 2024 May;41(5):1967-1982. doi: 10.1007/s12325-024-02830-z. Epub 2024 Mar 21.

Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study.

Adv Ther. 2018 Jan;35(1):43-55. doi: 10.1007/s12325-017-0651-3. Epub 2018 Jan 8.

A post-hoc pooled analysis to evaluate efficacy and safety of insulin glargine 300 U/mL in insulin-naïve people with type 2 diabetes with/without prior use of glucagon-like peptide-1 receptor agonist therapy.

Diabetes Res Clin Pract. 2024 Nov;217:111871. doi: 10.1016/j.diabres.2024.111871. Epub 2024 Sep 27.

Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: A review of the DELIVER programme.

Diabetes Obes Metab. 2021 Aug;23(8):1713-1721. doi: 10.1111/dom.14405. Epub 2021 Jun 1.

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).

Diabetes Obes Metab. 2015 Apr;17(4):386-94. doi: 10.1111/dom.12438. Epub 2015 Feb 12.

The economic value of insulin glargine 300 U/mL (Gla-300) in people ≥18 years of age with type 2 diabetes mellitus: a value-based economic model from a U.S. payer perspective.

J Med Econ. 2023 Jan-Dec;26(1):1469-1478. doi: 10.1080/13696998.2023.2277058. Epub 2023 Nov 11.

本文引用的文献

Towards the standardisation of adult person-reported outcome domains in diabetes research: A Consensus Statement development panel.

Diabet Med. 2024 Aug;41(8):e15332. doi: 10.1111/dme.15332. Epub 2024 May 15.

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Diabetes Care. 2022 Nov 1;45(11):2753-2786. doi: 10.2337/dci22-0034.

Real-world effectiveness and safety of insulin glargine 300 U/ml in insulin-naïve people with type 2 diabetes in the Latin America region: A subgroup analysis of the ATOS.

Diabetes Obes Metab. 2023 Jan;25(1):238-247. doi: 10.1111/dom.14868. Epub 2022 Oct 9.

Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naïve People with Type 2 Diabetes: the ATOS Study.

Diabetes Ther. 2022 Jun;13(6):1187-1202. doi: 10.1007/s13300-022-01266-4. Epub 2022 May 9.

Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review.

Diabetes Obes Metab. 2022 Mar;24(3):377-390. doi: 10.1111/dom.14603. Epub 2021 Dec 9.

Use of Diabetes Treatment Satisfaction Questionnaire in Diabetes Care: Importance of Patient-Reported Outcomes.

Int J Environ Res Public Health. 2018 May 9;15(5):947. doi: 10.3390/ijerph15050947.

Adherence to Insulin Therapy.

Diabetes Spectr. 2016 Aug;29(3):166-70. doi: 10.2337/diaspect.29.3.166.

Predictors of early discontinuation of basal insulin therapy in type 2 diabetes in primary care.

Prim Care Diabetes. 2016 Apr;10(2):142-7. doi: 10.1016/j.pcd.2015.08.001. Epub 2015 Aug 29.

Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials.

Diabetes Obes Metab. 2015 Sep;17(9):896-903. doi: 10.1111/dom.12527. Epub 2015 Jul 27.

New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1.

Diabetes Care. 2015 Apr;38(4):637-43. doi: 10.2337/dc14-0006. Epub 2014 Aug 22.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Clinically meaningful improvements in treatment satisfaction in insulin-naïve people with type 2 diabetes post initiation of insulin glargine 300 U/mL: A post hoc analysis of real-world ATOS study.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献